Last reviewed · How we verify

NCT04580680: GlobalARRT

Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)

Recruiting now Last updated 12 February 2025
What this trial tests

trial testing Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT) in Critical Illness in 1,000 participants. Currently enrolling.

Timeline
1 November 2020
Primary endpoint
30 September 2025
30 September 2025

Quick facts

Lead sponsorCareggi Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 November 2020
Primary completion30 September 2025
Estimated completion30 September 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Careggi Hospital

Who can join

Eligibility, any sex, with Critical Illness or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Worldwide, the use of Extracorporeal Blood Purification (EBP) in everyday clinical practice is becoming increasingly common, particularly in critical care settings. The efficacy of most of these treatments on removal of inflammatory mediators is the main rationale behind the use of EBP in critically ill patients with multiorgan dysfunction. Nonetheless, there are still some doubts as to the clinical efficacy of bacterial toxins and cytokines removal and many clinical trials aiming at exploring the effect of EBP on long-term outcomes of septic patients have failed to demonstrate consistent results regarding 28 day- or hospital-mortality rates. The primary aim of this observational prospective web-based registry is to define the possible clusters of critically ill patients - treated with extracorporeal blood purification therapies worldwide - who are homogeneous regarding both clinical and treatment characteristics and seem to benefit the most from EBP.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Rationale for sequential extracorporeal therapy (SET) in sepsis.
    Ronco C, Chawla L, Husain-Syed F, Kellum JA. · · 2023 · cited 47× · PMID 36750878 · DOI 10.1186/s13054-023-04310-2
  2. Survival benefit of resin cartridge extracorporeal blood purification therapy in patients with septic shock.
    Efe S, Hanci P, Inal V. · · 2024 · cited 2× · PMID 38812634 · DOI 10.55730/1300-0144.5773

Verify or expand the search:

Other trials of Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)

Trials testing the same drug.

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

Other Careggi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04580680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing